
    
      To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is
      effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized
      progesterone use increases maternal serum progesterone levels.
    
  